Novo Nordisk’s Defining Moment: Can a Pill Outweigh a Pipeline Setback?
The arithmetic of Novo Nordisk’s share price has become uncomfortably simple. At Monday’s close of 40.83 euros, the…
Novo Nordisk’s 5.27 Billion Kroner Buyback and UK Pill Nod Trump Cyber Setback
Novo Nordisk is deploying its balance sheet to send a message of confidence even as headwinds accumulate. The…
Novo Nordisk’s ADA Data: One Success, One Setback, and a Stock Under Pressure
Novo Nordisk shares drop 16% YTD after CagriSema fails non-inferiority vs Lilly’s Zepbound; Zenagamtide Phase 2 shows strong…
Novo Nordisk’s Brazilian Generic Setback Adds Urgency to ADA Pipeline Showcase
Brazil approves first generic Ozempic at 30% discount; Novo cuts Canada prices. All eyes on CagriSema Phase 3…
Novo Nordisk Battles Legal Setback and Pill Demand Slowdown as European Expansion Looms
Danish pharma giant faces Supreme Court pricing blow, Wegovy script slowdown, and Eli Lilly rivalry as Q1 revenue…
European Lithium’s Austrian Setback and Greenland Hopes Collide Over A$24 Million Squeeze
Austrian court blocks key permit for European Lithium’s Wolfsberg project, delaying FID to late 2026. Company faces A$24M…
European Lithium’s Clock Ticks Down as Austrian Setback Complicates Greenland Prize
European Lithium’s transatlantic merger hangs in balance amid Austrian court reversal, A$24M cash gap, and a 48-hour deadline,…